Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Takeda to Acquire ARIAD Pharmaceuticals
January 10, 2017
Takeda (Osaka, Japan) and ARIAD Pharmaceuticals, Inc. (Cambridge, MA) have entered into a definitive agreement under which Takeda will acquire all of the outstanding shares in ARIAD for $24.00 per share in cash, or an enterprise value of approximately $5.2 billion. The transaction is expected to close by the end of February 2017.
Takeda reports that the acquisition of ARIAD brings two innovative targeted therapies into its existing oncology portfolio: Brigatinib, for non-small cell lung cancer, and Iclusichronic, for chronic myeloid leukemia.
Takeda will leverage ARIAD’s R&D capabilities and platform, and largely absorb its R&D costs within Takeda's existing R&D budget.
Recent Videos
Related Content
